Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Soluble C5b-9 as a Biomarker for Complement Activation in Atypical Hemolytic Uremic Syndrome

14 May 2015

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Renal Diseases and Glomerulopathies

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 25818678
DOI: 10.1053/j.ajkd.2015.02.326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Soluble C5b-9 as a Biomarker for Complement Activation in Atypical Hemolytic Uremic SyndromePMID 25818678Read ↗

The Alternative Pathway of Complement and the Evolving Clinical-Pathophysiological Spectrum of Atypical Hemolytic Uremic SyndromeSemantic proximity Read ↗

Alternative complement pathway assessment in patients with atypical HUS.Semantic proximity Read ↗

Complement‐driven hemolytic uremic syndromeSemantic proximity Read ↗

Complement biology for hematologistsSemantic proximity Read ↗

Atypical hemolytic uremic syndrome: update on the complement system and what is new.Semantic proximity Read ↗

Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome.Semantic proximity Read ↗

A review of genetic and epigenetic biomarkers involved in the occurrence of atypical hemolytic uremic syndrome and its therapeutic strategies.Semantic proximity Read ↗

Atypical hemolytic uremic syndrome: the role of complement pathway gene mutation analysis.Semantic proximity Read ↗

Complement-mediated HUS revisited: evolving insights into pathophysiology, diagnosis, and treatment.Semantic proximity Read ↗

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUSSemantic proximity Read ↗

Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.